Oligonucleotide ligation assay detects HIV drug resistance associated with virologic failure among antiretroviral-naive adults in Kenya

Journal of Acquired Immune Deficiency Syndromes

Volumn 67, Issue 3, 2014, Pages 246-253

  Chung, Michael H ^a   Beck, Ingrid A ^b   Dross, Sandra ^a,b   Tapia, Kenneth ^a   Kiarie, James N ^c   Richardson, Barbra A ^a,d   Overbaugh, Julie ^d   Sakr, Samah R ^e   John Stewart, Grace C ^a   Frenkel, Lisa M ^a,b,f  

^a UNIVERSITY OF WASHINGTON   (United States)

^b SEATTLE BIOMEDICAL RESEARCH INSTITUTE   (United States)

^c UNIVERSITY OF NAIROBI   (Kenya)

^d USA   (United States)

^e Internal Medicine and Critical care Department   (Kenya)

^f UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

Antiretroviral therapy; HIV; Kenya; Oligonucleotide ligation assay; Transmitted drug resistance

Indexed keywords

LAMIVUDINE PLUS STAVUDINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; OLIGONUCLEOTIDE PROBE; RNA DIRECTED DNA POLYMERASE INHIBITOR; VIRUS DNA;

ADULT; ANTIVIRAL RESISTANCE; ANTIVIRAL SUSCEPTIBILITY; CD4 LYMPHOCYTE COUNT; CODON; CONFERENCE PAPER; DRUG DETERMINATION; FEMALE; FOLLOW UP; GENE MUTATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; KENYA; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; MUTATION RATE; NONHUMAN; NUCLEIC ACID ANALYSIS; OLIGONUCLEOTIDE LIGATION ASSAY; POINT MUTATION; PREVALENCE; PRIORITY JOURNAL; PYROSEQUENCING; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETROSPECTIVE STUDY; TRANSMITTED DRUG RESISTANCE; VIRUS LOAD; DIAGNOSTIC USE; DRUG EFFECTS; GENETICS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV INFECTIONS; ISOLATION AND PURIFICATION; LIGASE CHAIN REACTION; MIDDLE AGED; MOLECULAR DIAGNOSIS; MUTATION; OLIGONUCLEOTIDE PROBE; PROCEDURES; TREATMENT FAILURE; VIROLOGY;

ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DNA, VIRAL; DRUG RESISTANCE, VIRAL; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; KENYA; LIGASE CHAIN REACTION; MALE; MIDDLE AGED; MOLECULAR DIAGNOSTIC TECHNIQUES; MUTATION; OLIGONUCLEOTIDE PROBES; RETROSPECTIVE STUDIES; REVERSE TRANSCRIPTASE INHIBITORS; TREATMENT FAILURE; VIRAL LOAD;

EID: 84922016457     PISSN: 15254135     EISSN: 10779450     Source Type: Journal    
DOI: 10.1097/QAI.0000000000000312     Document Type: Conference Paper

References (28)

1. UNAIDS. Global Report: UNAIDS Report on the Global AIDS Epidemic 2012. Geneva: UNAIDS; 2012.
2. Jahn A, Floyd S, Crampin AC, et al. Population-level effect of HIV on adult mortality and early evidence of reversal after introduction of antiretroviral therapy in Malawi. Lancet. 2008;371:1603-1611.
3. Gupta RK, Jordan MR, Sultan BJ, et al. Global trends in antiretroviral resistance in treatment-naive individuals with HIV after rollout of antiretroviral treatment in resource-limited settings: a global collaborative study and meta-regression analysis. Lancet. 2012;380:1250-1258.
4. Stadeli KM, Richman DD. Rates of emergence of HIV drug resistance in resource-limited settings: a systematic review. Antivir Ther. 2012;18: 115-123.
5. Barth RE, Wensing AM, Tempelman HA, et al. Rapid accumulation of nonnucleoside reverse transcriptase inhibitor-associated resistance: evidence of transmitted resistance in rural South Africa. AIDS. 2008;22:2210-2212.
6. Jordan MR, Bennett DE, Wainberg MA, et al. Update on World Health Organization HIV drug resistance prevention and assessment strategy: 2004-2011. Clin Infect Dis. 2012;54(suppl 4):S245-S249.
7. Jourdain G, Wagner TA, Ngo-Giang-Huong N, et al. Association between detection of HIV-1 DNA resistance mutations by a sensitive assay at initiation of antiretroviral therapy and virologic failure. Clin Infect Dis. 2010;50:1397-1404.
8. Chung MH, Richardson BA, Tapia K, et al. A randomized controlled trial comparing the effects of counseling and alarm device on HAART adherence and virologic outcomes. PLoS Med. 2011;8:e1000422.
9. Chung MH, Drake AL, Richardson BA, et al. Impact of prior HAART use on clinical outcomes in a large Kenyan HIV treatment program. Curr HIV Res. 2009;7:441-446.
10. Emery S, Bodrug S, Richardson BA, et al. Evaluation of performance of the Gen-Probe human immunodeficiency virus type 1 viral load assay using primary subtype A, C, and D isolates from Kenya. J Clin Microbiol. 2000;38:2688-2695.
11. Beck IA, Mahalanabis M, Pepper G, et al. Rapid and sensitive oligonucleotide ligation assay for detection of mutations in human immunodeficiency virus type 1 associated with high-level resistance to protease inhibitors. J Clin Microbiol. 2002;40:1413-1419.
12. Micek MA, Blanco AJ, Beck IA, et al. Nevirapine resistance by timing of HIV type 1 infection in infants treated with single-dose nevirapine. Clin Infect Dis. 2010;50:1405-1414.
13. Beck IA, Deng W, Payant R, et al. Validation of an oligonucleotide ligation assay for quantification of human immunodeficiency virus type-1 (HIV) drug-resistant mutants using Massively parallel sequencing. J Clin Microbiol. 2014;52:2320-2327.
14. Liu TF, Shafer RW. Web resources for HIV type 1 genotypic-resistance test interpretation. Clin Infect Dis. 2006;42:1608-1618.
15. Beck IA, Crowell C, Kittoe R, et al. Optimization of the oligonucleotide ligation assay, a rapid and inexpensive test for detection of HIV-1 drug resistance mutations, for non-North American variants. J Acquir Immune Defic Syndr. 2008;48:418-427.
16. Arvold ND, Ngo-Giang-Huong N, McIntosh K, et al. Maternal HIV-1 DNA load and mother-to-child transmission. AIDS Patient Care STDS. 2007;21:638-643.
17. Deng W, Maust BS, Westfall DH, et al. Indel and Carryforward Correction (ICC): a new analysis approach for processing 454 pyrosequencing data. Bioinformatics. 2013;29:2402-2409.
18. Goodman DD, Zhou Y, Margot NA, et al. Low level of the K103N HIV-1 above a threshold is associated with virological failure in treatmentnaive individuals undergoing efavirenz-containing therapy. AIDS. 2011; 25:325-333.
19. Sigaloff KC, Mandaliya K, Hamers RL, et al. Short communication: high prevalence of transmitted antiretroviral drug resistance among newly HIV type 1 diagnosed adults in Mombasa, Kenya. AIDS Res Hum Retroviruses. 2012;28:1033-1037.
20. Lihana RW, Khamadi SA, Lubano K, et al. HIV type 1 subtype diversity and drug resistance among HIV type 1-infected Kenyan patients initiating antiretroviral therapy. AIDS Res Hum Retroviruses. 2009;25: 1211-1217.
21. Hamers RL, Wallis CL, Kityo C, et al. HIV-1 drug resistance in antiretroviral-naive individuals in sub-Saharan Africa after rollout of antiretroviral therapy: a multicentre observational study. Lancet Infect Dis. 2011;11:750-759.
22. Price MA, Wallis CL, Lakhi S, et al. Transmitted HIV type 1 drug resistance among individuals with recent HIV infection in East and Southern Africa. AIDS Res Hum Retroviruses. 2011;27:5-12.
23. Hassan AS, Mwaringa SM, Obonyo CA, et al. Low prevalence of transmitted HIV type 1 drug resistance among antiretroviral-naive adults in a rural HIV clinic in Kenya. AIDS Res Hum Retroviruses. 2013;29:129-135.
24. World Health Organization. Consolidated Guidelines on the Use of Antiretroviral Drugs for Treating and Preventing HIV Infection: Recommendations for a Public Health Approach. 2013 ed. Geneva: World Health Organization Press; 2013.
25. Little SJ, Holte S, Routy JP, et al. Antiretroviral-drug resistance among patients recently infected with HIV. N Engl J Med. 2002;347:385-394.
26. Wittkop L, Gunthard HF, de Wolf F, et al. Effect of transmitted drug resistance on virological and immunological response to initial combination antiretroviral therapy for HIV (EuroCoord-CHAIN joint project): a European multicohort study. Lancet Infect Dis. 2011;11:363-371.
27. Hamers RL, Schuurman R, Sigaloff KC, et al. Effect of pretreatment HIV-1 drug resistance on immunological, virological, and drug-resistance outcomes of first-line antiretroviral treatment in sub-Saharan Africa: a multicentre cohort study. Lancet Infect Dis. 2012;12:307-317.
28. Wagner TA, Kress CM, Beck I, et al. Detection of HIV-1 drug resistance in women following administration of a single dose of nevirapine: comparison of plasma RNA to cellular DNA by consensus sequencing and by oligonucleotide ligation assay. J Clin Microbiol. 2010;48:1555-1561.